Literature DB >> 9550357

Genotype-phenotype correlation in myotonic dystrophy.

E B Gharehbaghi-Schnell1, J Finsterer, I Korschineck, B Mamoli, B R Binder.   

Abstract

Myotonic dystrophy (DM) is caused by a mutation in the length of a trinucleotide (CTG) repeat in the 3' untranslated region of the myotonin protein kinase gene located on chromosome 19q13.3. The normal gene has between 5 and 36 CTG trinucleotide repeats, whereas minimally affected individuals have 50 copies and severely affected DM-patients have several thousands of such repeats. Since no information on a genotype phenotype correlation in Austrian DM-patients is available, we examined a small group of these patients for the unstable trinucleotide repeat. Molecular analysis was used to clarify equivocal clinical diagnoses and confirm clinical findings. We studied eight DM-families, a total of 57 individuals, of whom 18 were diagnosed with a trinucleotide repeat expansion. Twenty-six unrelated individuals served as a control. Clinical assessment was based on the muscular disability rating scale (MDRS) and a sum of symptoms score (SSS). There was a significant correlation between the clinical scores (MDRS: Spearman r = 0.51; p = 0.029: SSS: Spearman r = 0.538; p = 0.0259) used and the size of the amplification of the trinucleotide repeat. The largest expansion found in our group of patients was 6 kb. Furthermore, we observed both expansion and contraction of the enlarged fragment during transmission from one generation to the next.

Entities:  

Mesh:

Year:  1998        PMID: 9550357     DOI: 10.1034/j.1399-0004.1998.531530105.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  13 in total

1.  Myotonic dystrophy type I combined with X-linked dominant Charcot-Marie-Tooth neuropathy.

Authors:  Hyun Sook Kim; Ki Wha Chung; Sung Hee Kang; Sung Kyung Choi; Sun Young Cho; Heasoo Koo; Sang-Beom Kim; Byung-Ok Choi
Journal:  Neurogenetics       Date:  2010-05-05       Impact factor: 2.660

2.  Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases.

Authors:  Jean-Pierre Bouchard; Louise Cossette; Guillaume Bassez; Jack Puymirat
Journal:  J Neurol       Date:  2014-11-08       Impact factor: 4.849

3.  The Change of Grip Strength in a Patient with Congenital Myotonic Dystrophy Over a 4-year Period.

Authors:  Shin Kikuchi; Naoki Kozuka; Eiji Uchida; Takafumi Ninomiya; Haruyuki Tatsumi; Hidekatsu Takeda; Nobutada Tachi
Journal:  J Jpn Phys Ther Assoc       Date:  2008

4.  Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).

Authors:  Chad Heatwole; Rita Bode; Nicholas Johnson; Christine Quinn; William Martens; Michael P McDermott; Nan Rothrock; Charles Thornton; Barbara Vickrey; David Victorson; Richard Moxley
Journal:  Neurology       Date:  2012-07-11       Impact factor: 9.910

5.  HTS-Compatible Patient-Derived Cell-Based Assay to Identify Small Molecule Modulators of Aberrant Splicing in Myotonic Dystrophy Type 1.

Authors:  Debra A O'Leary; Leonardo Vargas; Orzala Sharif; Michael E Garcia; Yury J Sigal; Siu-Kei Chow; Christian Schmedt; Jeremy S Caldwell; Achim Brinker; Ingo H Engels
Journal:  Curr Chem Genomics       Date:  2010-03-19

6.  Lower gastrointestinal tract disturbance in congenital myotonic dystrophy.

Authors:  Tim P Kerr; Stephanie A Robb; Graham S Clayden
Journal:  Eur J Pediatr       Date:  2002-08       Impact factor: 3.183

7.  Detection of large expansions in myotonic dystrophy type 1 using triplet primed PCR.

Authors:  Susmita Singh; Amy Zhang; Stephen Dlouhy; Shaochun Bai
Journal:  Front Genet       Date:  2014-04-24       Impact factor: 4.599

8.  Elevated Muscle-Specific miRNAs in Serum of Myotonic Dystrophy Patients Relate to Muscle Disease Progress.

Authors:  Andrie Koutsoulidou; Tassos C Kyriakides; George K Papadimas; Yiolanda Christou; Evangelia Kararizou; Eleni Zamba Papanicolaou; Leonidas A Phylactou
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

9.  Prolonged Corrected QT Interval in Patients with Myotonic Dystrophy Type 1.

Authors:  Kang Min Park; Kyong Jin Shin; Sung Eun Kim; Jinse Park; Sam Yeol Ha; Byoung Joon Kim
Journal:  J Clin Neurol       Date:  2013-07-01       Impact factor: 3.077

10.  Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational Study.

Authors:  Celine Dogan; Marie De Antonio; Dalil Hamroun; Hugo Varet; Marianne Fabbro; Felix Rougier; Khadija Amarof; Marie-Christine Arne Bes; Anne-Laure Bedat-Millet; Anthony Behin; Remi Bellance; Françoise Bouhour; Celia Boutte; François Boyer; Emmanuelle Campana-Salort; Françoise Chapon; Pascal Cintas; Claude Desnuelle; Romain Deschamps; Valerie Drouin-Garraud; Xavier Ferrer; Helene Gervais-Bernard; Karima Ghorab; Pascal Laforet; Armelle Magot; Laurent Magy; Dominique Menard; Marie-Christine Minot; Aleksandra Nadaj-Pakleza; Sybille Pellieux; Yann Pereon; Marguerite Preudhomme; Jean Pouget; Sabrina Sacconi; Guilhem Sole; Tanya Stojkovich; Vincent Tiffreau; Andoni Urtizberea; Christophe Vial; Fabien Zagnoli; Gilbert Caranhac; Claude Bourlier; Gerard Riviere; Alain Geille; Romain K Gherardi; Bruno Eymard; Jack Puymirat; Sandrine Katsahian; Guillaume Bassez
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.